Supreme Court Won’t Hear Biolitec-AngioDynamics Case
This article was originally published in The Gray Sheet
The high court declined to hear arguments in the dispute between Biolitec and AngioDynamics on Nov. 30, leaving Biolitec responsible for damages and contempt of court penalties that could be as high as $160 million.
You may also be interested in...
Deal strengthens peripheral vascular product offerings with the addition of 510(k)-cleared blood clot removal system, which AngioDynamics expects will generate $50 million in annual sales in five years.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.